Wockhardt Q4 Results FY26 PAT Rs 166 Crore Turnaround from Rs 25 Crore Loss Novel Antibiotics Drive Recovery

Wockhardt Q4 results for FY26 delivered a consolidated net profit of Rs 166 crore, a dramatic turnaround from a net loss of Rs 25 crore in Q4 FY25. The Wockhardt Q4 results total income reached Rs 1,010 crore for the quarter. EPS for Q4 FY26 stood at Rs 10.22 per share versus Rs 3.61 in Q3 FY26, confirming the scale of the quarterly improvement.

The Wockhardt Q4 results reflect the pharmaceutical company’s ongoing business transformation driven by its novel antibiotic pipeline. Wockhardt’s WCK series of antibiotics targeting drug-resistant bacterial infections — including Zaynich (cefepime-zidebactam), Nafithromycin, and other candidates — represent a potential high-value franchise that could fundamentally re-rate the company’s earnings profile if regulatory approvals and commercial launches proceed as expected.

Get Free Stock Recommendations on Univest

Wockhardt Q4 FY26 Results at a Glance

Metric	Q4 FY26	Change / Context
Q4 Consolidated PAT	Rs 166 crore	Turnaround from loss Rs 25 crore in Q4 FY25
Q4 Total Income	Rs 1,010 crore	vs Rs 913 crore in Q3 FY26
Q4 EPS	Rs 10.22	vs Rs 3.61 in Q3 FY26
Key Pipeline	WCK novel antibiotic series	Drug-resistant bacteria treatment platform
Business Recovery	Pharma formulations improvement	Base business supporting turnaround

Track live Wockhardt financials, analyst ratings and peer comparisons on the Univest Screener.

Key Highlights from Wockhardt Q4 FY26 Results

Rs 166 Crore PAT Turnaround is the Largest Quarterly Swing in Wockhardt Q4 Results Recent History

The swing from a Rs 25 crore loss in Q4 FY25 to a Rs 166 crore profit in the Wockhardt Q4 results represents a Rs 191 crore year-on-year quarterly improvement — one of the largest absolute turnarounds in Wockhardt’s recent listed history. This Wockhardt Q4 results improvement reflects both base formulations business recovery and potentially meaningful contributions from the novel antibiotic product portfolio as initial commercialisation revenue begins.

Novel Antibiotic WCK Pipeline is Wockhardt Q4 Results Long-Term Re-Rating Catalyst

The WCK series of novel antibiotics in the Wockhardt Q4 results pipeline targets the critical unmet medical need of drug-resistant bacterial infections, particularly carbapenem-resistant infections that are a growing global health crisis. Regulatory approvals for these novel antibiotics in major markets including the US and EU would provide Wockhardt with premium-priced, patent-protected revenue streams that could be transformative for earnings. The Wockhardt Q4 results turnaround is an early signal that the transformation is underway.

What Drove Wockhardt Q4 FY26 Performance

The Wockhardt Q4 results turnaround was driven by improved base pharmaceutical formulations business performance in regulated markets including the UK, Germany, and other European markets, combined with early commercial traction from novel antibiotic products where initial launches are generating revenue. Cost rationalisation across the organisation also contributed to the improved margins visible in the Wockhardt Q4 results PAT swing.

Dividend and Capital Allocation

Wockhardt Q4 results FY26 capital allocation details including any dividend recommendation should be confirmed from the company’s exchange filing. Given the company’s ongoing investment in the novel antibiotic pipeline and the early stage of commercial launch for the WCK series, capital retention for R&D and regulatory affairs is likely prioritised in the current Wockhardt Q4 results period.

Outlook for FY27

Following the Wockhardt Q4 results, FY27 outlook is positive. The base formulations business recovery should sustain, and incremental novel antibiotic revenue from expanding WCK series commercial launches could provide meaningful earnings upside. Any major regulatory milestone for Zaynich in the US market would be a significant stock catalyst beyond the operational improvement visible in the Wockhardt Q4 results.

Conclusion

The Wockhardt Q4 results FY26 deliver one of the most compelling turnaround narratives of the Q4 season. PAT Rs 166 crore versus loss Rs 25 crore represents a Rs 191 crore year-on-year swing driven by base formulations recovery and novel antibiotic early commercialisation. The Wockhardt Q4 results signal that the years of investment in the WCK novel antibiotic pipeline are beginning to translate into commercial returns. FY27 monitoring should focus on WCK series regulatory approvals and launch revenues as the key re-rating catalysts.

Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.

Frequently Asked Questions

What was Wockhardt Q4 FY26 net profit?

Wockhardt Q4 results FY26 reported consolidated PAT of Rs 166 crore, a dramatic turnaround from a loss of Rs 25 crore in Q4 FY25. Total income reached Rs 1,010 crore and EPS stood at Rs 10.22, compared to Rs 3.61 in Q3 FY26.

What is the WCK novel antibiotic pipeline?

Wockhardt’s WCK novel antibiotic series includes Zaynich (cefepime-zidebactam) and Nafithromycin, targeting drug-resistant bacterial infections including carbapenem-resistant bacteria. The WCK pipeline represents a potential high-value patent-protected franchise that could significantly re-rate Wockhardt’s long-term earnings profile.

What drove Wockhardt Q4 FY26 turnaround?

Wockhardt Q4 results FY26 turnaround was driven by improved base pharmaceutical formulations business performance in regulated European markets, early commercial traction from novel antibiotic products, and cost rationalisation across operations. The combination of base business recovery and new product contribution drove the Rs 191 crore year-on-year improvement.

What is the FY27 outlook for Wockhardt?

Following Wockhardt Q4 results FY26, FY27 outlook is positive with base formulations sustaining recovery and incremental WCK series novel antibiotic revenue potentially adding meaningful upside. Any US FDA approval for Zaynich would be a significant catalyst. Consult a SEBI-registered advisor before investing.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026